Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001453687-23-000087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-11-15 | 2023-11-15 | RNAC | SPRINGER TIMOTHY A | Dir, 10% | A - Grant | $403.47 | +24.8K | 24.8K | New | +$10.00M |
| D | 2023-11-15 | 2023-11-15 | RNAC | SPRINGER TIMOTHY A | Dir, 10% | A - Grant | $403.47 | +123.9K | 123.9K | New | +$50.00M |
| DM | 2023-11-15 | 2023-11-13 | RNAC | SPRINGER TIMOTHY A | Dir, 10% | D - Sale to Iss | $0.93 | -201.4K | 0 | -100% | -$187.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series A Convertible Preferred Stock | 2023-11-15 | A | A | 24,785.08 | $403.47 | 24,785.08 | I See Footnote | — | — | (F1) Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. |
| 2 | Common | Series A Convertible Preferred Stock | 2023-11-15 | A | A | 123,925.41 | $403.47 | 123,925.41 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 6,410 | — | 0 | D | $17.47 · — to 2027-06-15 | 6,410 Common Stock | (F2) This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 10,000 | — | 0 | D | $12.75 · — to 2028-06-14 | 10,000 Common Stock | (F3) This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 10,000 | — | 0 | D | $2.10 · — to 2029-06-13 | 10,000 Common Stock | (F4) This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 75,000 | $0.93 | 0 | D | $1.13 · — to 2033-01-01 | 75,000 Common Stock | (F8) This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 40,000 | — | 0 | D | $4.01 · — to 2031-03-29 | 40,000 Common Stock | (F6) This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 40,000 | — | 0 | D | $3.31 · — to 2032-01-02 | 40,000 Common Stock | (F7) This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. |
| 9 | Derivative | Stock Option (Right to Buy) | 2023-11-13 | D | D | 20,000 | — | 0 | D | $3.00 · — to 2030-06-18 | 20,000 Common Stock | (F5) This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. |